Evaluation Pembrolizumab (Keytruda): CADTH Reimbursement Advice: Sign: Together with chemotherapy, for the remedy of Grownup patients with locally recurrent unresectable or metastatic triple-damaging breast most cancers which have not obtained prior chemotherapy for metastatic disorder and whose tumours Convey programmed mobile Loss of life-ligand